The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The Dystrophic Epidermolysis Bullosa Market has been comprehensively analyzed in IMARC's new report titled "Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast". Dystrophic epidermolysis bullosa refers to a rare genetic condition that causes the skin to blister or tear easily. The response could be to a minor injury or friction, such as rubbing or scratching or even from heat. The signs and symptoms of dystrophic epidermolysis bullosa generally differ among individuals. In mild cases, blistering may affect hands, feet, knees, and elbows, while in severe cases, widespread blistering occurs, which leads to scarring, vision loss, and other medical problems. The disease is diagnosed by identifying biallelic pathogenic variants (RDEB) or a heterozygous pathogenic variant (DDEB) in COL7A1 by molecular genetic testing. Currently, the available treatment focuses on managing symptoms and complications. Some of the common treatment available for dystrophic epidermolysis bullosa, include moisturizers to lessen friction and irritation, non-adhesive bandages and dressings to protect the wound, and medicines to ease the pain.
The rising incidences of rare genetic disorders coupled with the inflating demand for novel medications that can treat the conditions effectively are primarily driving the global dystrophic epidermolysis bullosa market. Besides this, the increasing patient willingness to pay for expensive treatments, such as gene therapy, cell-based therapy, molecular therapy, etc., is further augmenting the global market. Moreover, the emerging popularity of non-adhesive semiocclusive dressings, including soft silicone and foam dressings, for treating dystrophic epidermolysis bullosa since they absorb exudate and reduce pain and blister formation during dressing is also acting as another growth-inducing factor. In addition to this, numerous stakeholders are making significant investments in R&D activities to gain a clear understanding of the disease etiopathogenesis for developing new and cutting-edge therapy alternatives. This, in turn, is further creating a positive outlook for the market. Furthermore, the introduction of several treatment alternatives, such as stem cell transplantation and gene correction, is also bolstering the market growth. Additionally, the escalating need for more effective and personalized therapies with improved long-term side effect profiles is further expected to bolster the global dystrophic epidermolysis bullosa market in the coming years.
IMARC Group's new report "Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Dystrophic Epidermolysis Bullosa market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Dystrophic Epidermolysis Bullosa market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Dystrophic Epidermolysis Bullosa across the seven major markets. According to the report the United States has the largest patient pool for Dystrophic Epidermolysis Bullosa and also represents the largest market for Dystrophic Epidermolysis Bullosa treatment. Furthermore, the current Dystrophic Epidermolysis Bullosa treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Dystrophic Epidermolysis Bullosa market in any manner.
Time Period of the Study
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current Dystrophic Epidermolysis Bullosa marketed drugs and late-stage pipeline drugs.
In-Market Dystrophic Epidermolysis Bullosa Drugs
Late-Stage Pipeline Dystrophic Epidermolysis Bullosa Drugs
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
Pregnancy Detection Kits Market by Product (Home Pregnancy Tests (HPT), Digital Devices, and Others), Test Type (Urine Test for HCG, Blood Test for HCG, and Others), End User (Household, Gynecology Clinics, Hospitals), and Region 2023-2028
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at